UNSPSC 51143802: Caffeine/sodium benzoate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN809. This VA Drug Class (CN809) classifies this compound as belonging to the group CNS STIMULANTS, OTHER.

UNSPSC 51143802 Caffeine/sodium benzoate is a Commodity code, but the recent state and local opportunities tagged under it are soliciting pharmaceutical products, drug-deactivation systems, and over-the-counter items that fall outside the code's nominal scope — naloxone and safe drug deactivation systems for community health, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing. The mismatch suggests this code receives minimal authentic activity aligned to its narrow chemical-compound scope; when state and local buyers do tag opportunities here, they are typically addressing broader pharmaceutical procurement rather than caffeine or sodium benzoate as standalone products. The issuing bodies include county health departments (Seminole County, Florida), state health-and-human-services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local facilities).

Recent opportunities span three states and represent different procurement stages. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (a historical date suggesting data-entry error in the source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, seeking generic pharmaceuticals and OTC products from manufacturers for distribution through three authorized wholesalers, with responses due March 26, 2026, and contract effectiveness July 1, 2026. The geographic and issuing-body spread is narrow — primarily Florida, Texas, and Minnesota — suggesting this code sees limited recent state and local procurement activity in its authentic commodity scope.